We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

35 hedge funds and large institutions have $1.72M invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 34 → 35 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

12% less capital invested

Capital invested by funds: $1.94M → $1.72M (-$226K)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

Holders
35
Holders Change
+1
Holders Change %
+2.94%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
5
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
VF
Virtu Financial
New York
+$9.38K
2
Bank of America
Bank of America
North Carolina
+$8.75K
3
PCM
Perkins Capital Management
Minnesota
+$7.73K
4
Jane Street
Jane Street
New York
+$2.39K
5
TSS
Two Sigma Securities
New York
+$1.26K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$131K
2
CM
CM Management
Florida
-$53.1K
3
Renaissance Technologies
Renaissance Technologies
New York
-$26K
4
E
Ergoteles
New York
-$7.21K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$4.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$505K – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$231K – – –
DCMIC
3
Decheng Capital Management III (Cayman)
Cayman Islands
$185K – – –
CMU
4
Carnegie Mellon University
Pennsylvania
$174K – – –
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$117K – – –
KAS
6
Kestra Advisory Services
Texas
$94.3K – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$69.7K -$131K -28,446 -60%
JAMONY
8
Jacob Asset Management of New York
California
$57.9K – – –
PCM
9
Prelude Capital Management
New York
$57.5K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$43.3K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$32K -$26K -5,630 -39%
PCM
12
Perkins Capital Management
Minnesota
$25K +$7.73K +1,675 +34%
CM
13
CM Management
Florida
$22K -$53.1K -11,500 -66%
WPW
14
Waldron Private Wealth
Pennsylvania
$14.7K – – –
BlackRock
15
BlackRock
New York
$14.1K +$466 +101 +3%
State Street
16
State Street
Massachusetts
$12.7K – – –
Northern Trust
17
Northern Trust
Illinois
$10.2K – – –
Bank of America
18
Bank of America
North Carolina
$9.98K +$8.75K +1,895 +236%
VF
19
Virtu Financial
New York
$8K +$9.38K +2,031 New
DC
20
Davenport & Co
Virginia
$5.55K -$2.42K -525 -26%
Charles Schwab
21
Charles Schwab
California
$5.5K – – –
TSS
22
Two Sigma Securities
New York
$4.29K +$1.26K +274 +31%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$3.56K -$4.3K -932 -49%
Mariner
24
Mariner
Kansas
$3K – – –
TRCT
25
Tower Research Capital (TRC)
New York
$3K +$5 +1 +0.1%
1
2

NBSE Hedge Fund Activity: Q1 2023 in Review

35 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2023, worth a combined $1.72M — down 12% from $1.94M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NBSE positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $9.38K. The largest seller was Vanguard Group, cutting an estimated $131K.

  • 35 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2023, up from 34 in Q4 2022.
  • Funds reported $1.72M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2023, down 12% quarter-over-quarter.
  • 4 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2023 and 3 closed out, a net change of +1 holder.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2023 was Virtu Financial, an estimated $9.38K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2023 was Vanguard Group, an estimated $131K sold.

Based on aggregated 13F filings for Q1 2023.